Bold Therapeutics, Inc.
🇨🇦Canada
- Country
- 🇨🇦Canada
- Ownership
- Holding
- Established
- 2018-01-01
- Employees
- 11
- Market Cap
- -
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Phase 1
Recruiting
- Conditions
- Colorectal CancerPancreatic CancerCholangiocarcinomaGastric Cancers
- Interventions
- Drug: BOLD-100 in combination with FOLFOX Chemotherapy (Dose Expansion)Drug: BOLD-100 in combination with FOLFOX Chemotherapy (Dose Escalation)
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Bold Therapeutics, Inc.
- Target Recruit Count
- 220
- Registration Number
- NCT04421820
- Locations
- 🇨🇦
Cross Cancer Institue, Edmonton, Alberta, Canada
🇰🇷Kangbuk Samsung Hospital, Seoul, Korea, Republic of
🇺🇸University of California, Los Angeles, Santa Monica, California, United States
© Copyright 2025. All Rights Reserved by MedPath